Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Xcure Corp (070300:KRX), powered by AI.
Xcure Corp is currently trading at ₩1,996. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Xcure Corp on Alpha Lenz.
Xcure Corp's P/E ratio is 303.8.
“Xcure Corp trades at a P/E of 303.8 (premium valuation) with modest ROE of 0.9%. 3Y revenue CAGR of 21.7% highlights clear growth momentum.”
Ask for details →Xcure Corp is a biotechnology company at the forefront of developing innovative solutions in the healthcare sector. This organization is primarily engaged in the research and development of cutting-edge therapies designed to address unmet medical needs globally. Xcure Corp's significant focus is on creating and enhancing pharmaceutical treatments that tackle complex and high-demand diseases, contributing to advancements in medical science. By leveraging advanced biotechnological methods and collaborating with key players in the healthcare industry, the company plays a vital role in pioneering new treatment options for patients worldwide. Its efforts not only influence the biotech and pharmaceutical sectors but also have substantial implications across healthcare markets, affecting regulatory frameworks and clinical practices. Xcure Corp stands as a critical player in the dynamic landscape of medical innovation, continually investing in research and strategic partnerships to expand its influence and drive progress within the life sciences field.
“Xcure Corp trades at a P/E of 303.8 (premium valuation) with modest ROE of 0.9%. 3Y revenue CAGR of 21.7% highlights clear growth momentum.”
Ask for details →Xcure Corp (ticker: 070300) is a company listed on KRX in the Technology sector (Communication Equipment). It has approximately 32 employees. Market cap is $70.9B.
The current price is ₩1,996 with a P/E ratio of 303.78x and P/B of 2.23x.
ROE is 0.89% and operating margin is 10.26%. Annual revenue is $18.5B.